ThinkPatternGet the app
Story
BUSINESS · NOV 16, 2026

Leo Pharma Delays IPO Beyond 2026 Due to Volatility

Leo Pharma postponed its initial public offering beyond 2026, citing unsuitable market conditions despite reporting a 9% increase in nine-month revenue.

Leo Pharma delayed its planned initial public offering beyond 2026, citing market volatility as the primary reason for the postponement. CEO Christophe Bourdon stated that while the company is prepared for a listing, its shareholders determined that current market conditions do not support a debut.

The company's ownership is divided between the LEO Foundation, which holds an 80% stake, and the private equity firm Nordic Capital, which holds 20%. Bourdon described an IPO as a "natural and viable option" but declined to set a new timeline, noting that future plans depend on investor appetite and business performance.

Despite the listing delay, the Danish drugmaker reported a 9% revenue increase to 10.96 billion kroner for the first nine months of the year. The company maintained its 2026 revenue growth outlook of 9% to 11% at constant exchange rates.


Reported across 2 outlets
Actors
Leo PharmaChristophe BourdonNordic Capital

Keep reading in the app

The full story and every source, free in the app.